The “Build A Bear” version of Gene Editing — go splice your own gene.
The biohacking movement has created a wealth of options for hobbyist scientists. In Brooklyn, a DIY lab offers a place for the curious to dabble.
Read more
Category: bioengineering – Page 222
Now, that’s an exhibit!
May 5, 2016, will mark the opening of a new and exciting exhibit at Chicago’s famed Museum of Science and Industry: an in-depth and interactive look behind the curtain at the Defense Advanced Research Projects Agency (DARPA).
DARPA was created in 1958 at the peak of the Cold War in response to the Soviet Union’s launch of Sputnik, the world’s first manmade satellite, which passed menacingly over the United States every 96 minutes. Tasked with preventing such strategic surprises in the future, the agency has achieved its mission over the years in part by creating a series of technological surprises of its own, many of which are highlighted in the Chicago exhibit, “Redefining Possible.”
“We are grateful to Chicago’s Museum of Science and Industry for inviting us to tell the DARPA story of ambitious problem solving and technological innovation,” said DARPA Deputy Director Steve Walker, who will be on hand for the exhibit’s opening day. “Learning how DARPA has tackled some of the most daunting scientific and engineering challenges—and how it has tolerated the risk of failure in order to have major impact when it succeeds—can be enormously inspiring to students. And for adults, we hope the exhibit will serve as a reminder that some of the most exciting work going on today in fields as diverse as chemistry, engineering, cyber defense and synthetic biology are happening with federal support, in furtherance of pressing national priorities.”
Read more
Excellent read and a true point about the need for some additional data laws with our ever exploding information overload world.
Laws for Mobility, IoT, Artificial Intelligence and Intelligent Process Automation
If you are the VP of Sales, it is quite likely you want and need to know up to date sales numbers, pipeline status and forecasts. If you are meeting with a prospect to close a deal, it is quite likely that having up to date business intelligence and CRM information would be useful. Likewise traveling to a remote job site to check on the progress of an engineering project is also an obvious trigger that you will need the latest project information. Developing solutions integrated with mobile applications that can anticipate your needs based upon your Code Halo data, the information that surrounds people, organizations, projects, activities and devices, and acting upon it automatically is where a large amount of productivity gains will be found in the future.
There needs to be a law, like Moore’s infamous law, that states, “The more data that is collected and analyzed, the greater the economic value it has in aggregate.” This law I believe is accurate and my colleagues at the Center for the Future of Work, wrote a book titled Code Halos that documents evidence of its truthfulness as well. I would also like to submit an additional law, “Data has a shelf-life and the economic value of data diminishes over time.” In other words, if I am negotiating a deal today, but can’t get the critical business data I need for another week, the data will not be as valuable to me then. The same is true if I am trying to optimize, in real-time, the schedules of 5,000 service techs, but don’t have up to date job status information. Receiving job status information tomorrow, does not help me optimize schedules today.
Read more
Scientists are now one step closer to neutralizing HIV.
In a study conducted at Vanderbilt University and published in Proceedings of the National Academy of Sciences, researchers isolated antibodies with a loop-like structure that binds tightly to HIV and disables it. Unlike traditional vaccines, which jump-start an immune response by exposing the patient to a pathogen, this newly discovered method could work even in people who have not previously been exposed to by the virus.
Using computer modeling, the researchers identified the amino acid sequences that bound most tightly to HIV and re-engineered them in an optimal sequence that simulated vaccination.
Read more
New research by UCSF scientists could accelerate – by 10 to 100-fold – the pace of many efforts to profile gene activity, ranging from basic research into how to build new tissues from stem cells to clinical efforts to detect cancer or auto-immune diseases by profiling single cells in a tiny drop of blood.
The study, published online April 27, 2016, in the journal Cell Systems, rigorously demonstrates how to extract high-quality information about the patterns of gene expression in individual cells without using expensive and time-consuming deep-sequencing technology. The paper’s senior authors are Hana El-Samad, PhD, an associate professor of biochemistry and biophysics at UCSF, and Matt Thomson, PhD, a faculty fellow in UCSF’s Center for Systems and Synthetic Biology.
“We believe the implications are huge because of the fundamental tradeoff between depth of sequencing and throughput, or cost,” said El-Samad. “For example, suddenly, one can think of profiling a whole tumor at the single cell level.”
Read more
In a new study, researchers detail the culturing and transfecting of cells with genetic material on an array of carbon nanotubes, which appears to overcome the limitations of other gene editing technologies.
Gene editing techniques hold great promise. They allow targeted and specific edits of genes, and have nearly limitless possibilities in the field of medicine.
Which is not to say that they are perfect. These techniques still have a range of limitations, from precision to toxicity. But a new study shows that can be changed.
Read more
Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.
This first trial, within the portfolio of Bioquark’s Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.
“We are very excited about the approval of our protocol,” said Ira S. Pastor, CEO, Bioquark Inc. “With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies.”
Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.
While human beings lack substantial regenerative capabilities in the CNS, many non-human species, such as amphibians, planarians, and certain fish, can repair, regenerate and remodel substantial portions of their brain and brain stem even after critical life-threatening trauma.
Additionally, recent studies on complex brain regeneration in these organisms, have highlighted unique findings in relation to the storage of memories following destruction of the entire brain, which may have wide ranging implications for our understanding of consciousness and the stability of memory persistence.
“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer’s and Parkinson’s disease,” said Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.
Over the years, clinical science has focused heavily on preventing such life and death transitions and made some initial progress with suspended animation technologies, such as therapeutic hypothermia. However, once humans transition through the brain death window, currently defined by the medical establishment as “irreversible”, they are technically no longer alive, despite the fact that human bodies can still circulate blood, digest food, excrete waste, balance hormones, grow, sexually mature, heal wounds, spike a fever, and gestate and deliver a baby. It is even acknowledged by thought leaders that recently brain dead humans still may have residual blood flow and electrical nests of activity in their brains, just not enough to allow for an integrated functioning of the organism as a whole.
“We look forward to working closely with Bioquark Inc. on this cutting edge clinical initiative,” said Dr. Himanshu Bansal, Managing Director of Revita Life Sciences.
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
About Revita Life Sciences
Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, PhD. who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.
CRISPR to improve shelf life of vegetables and fruits. I magine what this would mean for populations in remote locations with horrible climates or in disaster zones that need fresh foods.
Yinong Yang, a Penn State University researcher, has used a famous gene editing tool known as CRISPR/Cas9 for cutting out a small piece of DNA from one specific gene in a white button mushroom. With this, Yang was able to stop the gene, which in turn cuts the production of an enzyme known as polyphenol oxidase in mushroom. With this gene editing of white mushrooms, the mushroom doesn’t get spoiled as natural mushrooms.
You might have heard something like this earlier as scientists have also developed non-browning versions of apples and potatoes. However, those crops were called GMOs as scientists had put in new, slightly altered genes within those plants to ‘silence’ the natural gene.
Last fall, Yang wrote a letter to the US Department of Agriculture, wherein he asked whether his mushroom would be subject to regulation by the USDA. The USDA replied this week saying no.
Read more
